Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 27312437.
- Also identified by DOI 10.1016/j.kint.2016.05.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Posttrial follow-up of participants randomized to intensive versus standard glycemic control in the ADVANCE trial has demonstrated a significant benefit of intensive glycemic control on the risk of end-stage renal disease. In a more detailed analysis, intensive glycemic control appears to be of benefit only before the development of clinically evident kidney disease or in patients with documented early-stage chronic kidney disease.
Medical subject headings
- Blood Glucose
- Kidney Failure, Chronic